Literature DB >> 3046930

Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats.

S M Brichard1, W Okitolonda, J C Henquin.   

Abstract

The trace element vanadium (V) exerts insulin-like effects in vitro. The present study examined its effects on glucose homeostasis in rats made diabetic by streptozotocin. Na3VO4 (0.2 or 0.5 mg/ml) was administered ad libitum in drinking water. Fed plasma glucose levels (approximately 26 mmol/liter) fell by 30% and 56% after 5 days of treatment with the low (VO.2) and high (VO.5) concentrations of vanadate, respectively. This decrease was not due to a rise in peripheral insulin levels and persisted for more than 2 months. Daily glucosuria was decreased by 60% and 85% in VO.2 and VO.5 rats, respectively. Tolerance of the rats to oral or iv glucose was also considerably improved by vanadate; integrated glucose responses were about 55% and 75% lower in VO.2 and VO.5 rats than in controls, and the differences were not due to restoration of insulin release. Compared to nondiabetic rats, pancreatic insulin reserves amounted to 1% in untreated rats, 3% in VO.2 rats, and 6% in VO.5 rats after 9 weeks of treatment. Liver, but not muscle, glycogen was increased by vanadate. Despite improvement of their diabetic state, vanadate-treated rats did not gain more weight than untreated rats. Their food intake (corrected for urinary glucose losses) was decreased by about 25%. No signs of altered kidney or liver function were observed in rats receiving vanadate. In conclusion, vanadate markedly improves glucose homeostasis in streptozotocin-diabetic rats by an insulin-like mechanism, but does not reproduce the anabolic effects of the hormone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046930     DOI: 10.1210/endo-123-4-2048

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  38 in total

1.  Vanadium and diabetes. What about vanadium toxicity?

Authors:  J L Domingo
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

Review 2.  Anti-diabetic and toxic effects of vanadium compounds.

Authors:  A K Srivastava
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 3.  Clinical implications of trace elements in endocrinology.

Authors:  J Neve
Journal:  Biol Trace Elem Res       Date:  1992 Jan-Mar       Impact factor: 3.738

4.  Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase.

Authors:  M Bollen; M Miralpeix; F Ventura; B Toth; R Bartrons; W Stalmans
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

Review 5.  Effects of vanadyl derivatives on animal models of diabetes.

Authors:  G Cros; J J Mongold; J J Serrano; S Ramanadham; J H McNeill
Journal:  Mol Cell Biochem       Date:  1992-02-12       Impact factor: 3.396

6.  Toxic effects of vanadium in streptozotocin-treated rats after administration of vanadate to normalize blood glucose levels.

Authors:  J L Domingo; J M Llobet; J Corbella
Journal:  Diabetologia       Date:  1990-01       Impact factor: 10.122

7.  Oral selenate improves glucose homeostasis and partly reverses abnormal expression of liver glycolytic and gluconeogenic enzymes in diabetic rats.

Authors:  D J Becker; B Reul; A T Ozcelikay; J P Buchet; J C Henquin; S M Brichard
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

Review 8.  Alternative therapies for diabetes and its cardiac complications: role of vanadium.

Authors:  Tod A Clark; Justin F Deniset; Clayton E Heyliger; Grant N Pierce
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 9.  Vanadium and diabetes.

Authors:  P Poucheret; S Verma; M D Grynpas; J H McNeill
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

10.  Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B.

Authors:  Thomas Scior; José Antonio Guevara-García; F J Melendez; Hassan H Abdallah; Quoc-Tuan Do; Philippe Bernard
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.